1. Home
  2. VERU
Logo Veru Inc.

VERU

Veru Inc.

as 11-21-2025 3:16pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Founded: 1971 Country:
United States
United States
Employees: N/A City: MIAMI
Market Cap: 40.6M IPO Year: 1990
Target Price: $25.00 AVG Volume (30 days): 191.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.23 EPS Growth: N/A
52 Week Low/High: $2.11 - $14.20 Next Earning Date: 12-15-2025
Revenue: $16,886,419 Revenue Growth: 337.24%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

VERU Daily Stock ML Predictions

Share on Social Networks: